GENOMIC EXPRESSION
OperatingGenomic Expression Inc.
Healthcare · Technology · Beverly, NY · Founded 2009
Saving lives now, one cancer patient at a time
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
8 people
Scientist, CEO, and company builder with a focus on improving health and sustainability through innovative RNA technologies. Former executive at Novo Nordisk and advisor to the Danish Government and European Commission on innovation policies. Holds an MSc and BA in international trade.
Genetics postdoc and serial entrepreneur with expertise in nucleic acid-based chemistries. Co-inventor of novel Next Generation Sequencing and synthetic biology technologies. Has filed patents across the USA, Europe, and Canada. Passionate about advancing scientific research and innovation.
Co-Founder and Executive Chairman of NextWaveBio, focused on developing affordable medicines. Former CEO of Protein Sciences, leading the development of the first recombinant influenza vaccine. A biotechnology pioneer with a history of building successful companies in the industry.
Seasoned executive with extensive experience in R&D, particularly in dermatology and infectious diseases. Founder and CEO of multiple biotech firms, raising over $300 million. Currently, Managing Partner at Phases123 LLC and Co-Founder of Legacy Health Care, with a focus on strategic growth and innovation.
Jesper Zeuthen holds a degree in molecular biology from the University of Copenhagen and a D.Sc. in biology. He has held positions at the Karolinska Institute, Novo, and the Danish Cancer Society. Jesper co-founded biotech companies, notably Genmab. He supports early cancer detection and genetic analysis to guide treatment, aligning with Genomic Expression's vision to "make cancer history."
Experienced manager with strategic expertise in business development and digitalization. Industry background in technology, life sciences, construction, and finance. Board member in health businesses, known for her energetic and enterprising approach to business strategy and operations.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.